MATERIALS AND METHODS
Study staff performed a retrospective chart review from the medical records of patients diagnosed with MF who were prescribed BV at Atrium Health Wake Forest Baptist Comprehensive Cancer Center.
RESULTS
Of the eight patients identified as receiving at least one dose of BV, 37.5% of patients had an initial skin biopsy that showed CD30 positivity defined as having at least 5% of T cells expressing CD30, 37.5% of patients had initial CD30 negative biopsy but had subsequent skin biopsies that exhibited CD30 positivity, and 25% of patients never had CD30 checked on their biopsy (Table 1).
DISCUSSION
BV appears to be more effective against CD30-expressing CTCL compared to current standard-of-care regimens.3 Inconsistencies in CD30 detection methods can limit utilization of targeted therapies like BV for CTCL.3 In our study, objective positive response was observed irrespective of CD30 expression on initial biopsy reports. All patients in our cohort had higher CD30 positivity on subsequent biopsies compared to their initial skin biopsy regardless of BV response (Table 1). One explanation for this finding may be due to a lack of sensitivity to the assay used to detect cell-surface CD30 expression.4 Improved understanding of appropriate CD30 testing and evaluation will allow more patients with BV responsive CTCL to be identified and treated.3
DISCLOSURES
Steven Feldman has received research, speaking and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation. He is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients' adherence to treatment. Lindsay Strowd has received research funding, grants, or honoraria from Sanofi, Regeneron, Pfizer, Galderma, Lilly, Novartis and Arcutis. Katherine Kelly, Mary Beth Seegars, Rakhee Vaidya, and Leah Edenfield have no conflicts of interest to disclose.
REFERENCES
- Kamijo H, Miyagaki T. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy. Current Treatment Options in Oncology. 2021;22(2). doi:10.1007/s11864-020-00809-w
- Prince HM, Kim YH, Horwitz S, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. The Lancet. 2017;390(10094). doi:10.1016/S0140-6736(17)31266-7
- Karube K, Kakimoto Y, Tonozuka Y, et al. The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas. Expert Review of Hematology. 2021;14(8). doi:10.1080/17474086.2021.1955344
- Kim YH, Prince HM, Whittaker S, et al. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. European Journal of Cancer. 2021;148. doi:10.1016/j.ejca.2021.01.054
AUTHOR CORRESPONDENCE
Katherine Kelly BS katkelly@wakehealth.edu
